Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%

This article was originally published in The Gray Sheet

Executive Summary

Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May

You may also be interested in...

Cyberonics Cuts Investment In VNS Depression Indication; Q4 Sales Up 64%

Cyberonics expects to scale-back its investment in developing a depression indication for its NeuroCybernetic Prosthesis vagus nerve stimulation system by 25% in fiscal 2003

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts